Scinai Immunotherapeutics stock surges 55% on breakthrough psoriasis treatment results

Scinai Immunotherapeutics Ltd (NASDAQ: SCNI) unveiled promising preclinical outcomes for its innovative anti IL-17A/F antibody fragment (NanoAb) aimed at treating mild to moderate plaque psoriasis.  The biotechnology firm’s shares experienced a significant surge of 55% this morning after the announcement, but despite this increase, they are still down approximately 35% from their highest point over […]